BREG Introduces Full Line of FUSION(R) Functional Knee Braces; Family of Braces Includes FUSION, FUSION XT, FUSION Women's & FUSION OA.

HUNTERSVILLE, N.C. -- BREG, Inc., a leading medical device company specializing in premium orthopedic, rehabilitative and post-operative products, and a division of Orthofix International, N.V. (NASDAQ: OFIX), today announced immediate availability of its full line of FUSION functional knee braces, including FUSION, FUSION XT, FUSION Women's and FUSION OA.

BREG's FUSION braces are a revolutionary advancement in bracing technology. Unlike traditional functional knee braces, FUSION works in tandem with the knee to provide optimum protection of the ACL, PCL and collateral ligaments--without hindering mobility. By incorporating BREG's proprietary ProForm(TM) technology, which utilizes Zytel(R), a strong yet flexible polymer, each FUSION brace conforms intimately with the leg for a low profile, contoured fit. This allows the brace to remain in place through all levels of activity, thus permitting unhindered motion and enhanced protection while also providing superior comfort and suspension.

"In developing FUSION, we assessed the diverse needs of patients and developed a brace that people want to wear," said Brad Mason, president of BREG. "Most functional knee braces are heavy and uncomfortable--and they tend to migrate, which leads to non-compliance. We designed FUSION to address these common problems. FUSION is sleek and lightweight, intimately conforms to the leg, and protects as well as its more cumbersome counterparts. Best of all, patients hardly know it's on."

FUSION XT, the first brace in the FUSION family, was released in July 2005. Designed specifically for contact sports, FUSION XT helped the company to significantly grow its market share in the segment with more than 215 college and professional teams using the brace since its release.

"Because BREG's FUSION XT launch has been so successful, we have high expectations that the launch of these additional products in the FUSION line will enable BREG to substantially grow its market share for functional braces," said Alan Milinazzo, group president and CEO of Orthofix. "Indeed, with this extraordinary new family of braces, BREG expects to set a new standard in bracing."

The full line of FUSION braces, including FUSION, FUSION XT, FUSION Women's, and FUSION OA, are available in custom and off-the-shelf versions.

For more information about FUSION visit www.freedomtoperform.com or www.breg.com.

About BREG, Inc.

Since 1989 BREG, Inc., a division of Orthofix International N.V. (NASDAQ: OFIX), has pioneered premium orthopedic, reconstructive and postoperative products. With a solid commitment to customer-driven innovation, BREG has established itself as a leader in the industry by continually delivering world-class solutions that address the critical needs of its customers. Based in Vista, California, BREG's products are currently distributed through a worldwide network of more than 100 distributors in 36 countries. The company's extensive product offerings including postoperative pain management products, CPM devices, and a full range of soft goods and functional knee braces are designed to meet the changing needs of its customers worldwide. BREG also offers inventory management services and solutions to create overall practice management efficiencies for health care providers. For more information visit www.breg.com.

About Orthofix International, N.V.

Orthofix International N.V., a global diversified orthopedic products company, offers a broad line of minimally invasive surgical, and non-surgical products for the Spine, Reconstruction, and Trauma market sectors that address the lifelong bone-and-joint health needs of patients of all ages -- helping them achieve a more active and mobile lifestyle. Orthofix's products are widely distributed around the world to orthopedic surgeons and patients via Orthofix's sales representatives and its subsidiaries, including BREG, Inc., and via partnerships with other leading orthopedic product companies, such as Medtronic Sofamor Danek and Kendall Healthcare. In addition, Orthofix is collaborating in R&D partnerships with leading medical institutions such as the Orthopedic Research and Education Foundation, Rutgers University, the Cleveland Clinic Foundation and the National Osteoporosis Institute. For more information about Orthofix, please visit www.orthofix.com.

Forward-Looking Statements

This news release contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of Orthofix, and are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to unanticipated expenditures, changing relationship with customers, suppliers and strategic partners, risks relating to the protection of intellectual property, changes to the reimbursement policies of third parties, changes to governmental regulation of medical devices, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the orthopedic industry and the economy and other factors described in the most recent report on Form 10-K and other periodic reports filed by Orthofix with the Securities and Exchange Commission.